全文获取类型
收费全文 | 24424篇 |
免费 | 1545篇 |
国内免费 | 865篇 |
专业分类
耳鼻咽喉 | 254篇 |
儿科学 | 170篇 |
妇产科学 | 106篇 |
基础医学 | 2395篇 |
口腔科学 | 694篇 |
临床医学 | 1976篇 |
内科学 | 1693篇 |
皮肤病学 | 98篇 |
神经病学 | 1820篇 |
特种医学 | 1394篇 |
外国民族医学 | 1篇 |
外科学 | 4903篇 |
综合类 | 2820篇 |
一般理论 | 1篇 |
预防医学 | 684篇 |
眼科学 | 149篇 |
药学 | 5524篇 |
5篇 | |
中国医学 | 1551篇 |
肿瘤学 | 596篇 |
出版年
2023年 | 302篇 |
2022年 | 453篇 |
2021年 | 799篇 |
2020年 | 677篇 |
2019年 | 780篇 |
2018年 | 769篇 |
2017年 | 769篇 |
2016年 | 656篇 |
2015年 | 726篇 |
2014年 | 1408篇 |
2013年 | 1946篇 |
2012年 | 1323篇 |
2011年 | 1414篇 |
2010年 | 1168篇 |
2009年 | 1167篇 |
2008年 | 1091篇 |
2007年 | 1101篇 |
2006年 | 940篇 |
2005年 | 844篇 |
2004年 | 703篇 |
2003年 | 726篇 |
2002年 | 567篇 |
2001年 | 508篇 |
2000年 | 479篇 |
1999年 | 442篇 |
1998年 | 387篇 |
1997年 | 338篇 |
1996年 | 294篇 |
1995年 | 327篇 |
1994年 | 293篇 |
1993年 | 264篇 |
1992年 | 248篇 |
1991年 | 209篇 |
1990年 | 214篇 |
1989年 | 214篇 |
1988年 | 177篇 |
1987年 | 154篇 |
1986年 | 166篇 |
1985年 | 220篇 |
1984年 | 223篇 |
1983年 | 150篇 |
1982年 | 206篇 |
1981年 | 190篇 |
1980年 | 158篇 |
1979年 | 118篇 |
1978年 | 116篇 |
1977年 | 88篇 |
1976年 | 100篇 |
1975年 | 62篇 |
1974年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):591-604.e3
ObjectivesGuidelines suggest aortic valve replacement (AVR) for low-risk asymptomatic patients. Indications for transcatheter AVR now include low-risk patients, making it imperative to understand state-of-the-art surgical AVR (SAVR) in this population. Therefore, we compared SAVR outcomes in low-risk patients with those expected from Society of Thoracic Surgeons (STS) models and assessed their intermediate-term survival.MethodsFrom January 2005 to January 2017, 3493 isolated SAVRs were performed in 3474 patients with STS predicted risk of mortality <4%. Observed operative mortality and composite major morbidity or mortality were compared with STS-expected outcomes according to calendar year of surgery. Logistic regression analysis was used to identify risk factors for these outcomes. Patients were followed for time-related mortality.ResultsWith 15 observed operative deaths (0.43%) compared with 55 expected (1.6%), the observed:expected ratio was 0.27 for mortality (95% confidence interval [CI], 0.14-0.42), stroke 0.65 (95% CI, 0.41-0.89), and reoperation 0.50 (95% CI, 0.42-0.60). Major morbidity or mortality steadily declined, with probabilities of 8.6%, 6.7%, and 5.2% in 2006, 2011, and 2016, respectively, while STS-expected risk remained at approximately 12%. Mitral valve regurgitation, ventricular hypertrophy, pulmonary, renal, and hepatic failure, coronary artery disease, and earlier surgery date were residual risk factors. Survival was 98%, 91%, and 82% at 1, 5, and 9 years, respectively, superior to that predicted for the US age-race-sex–matched population.ConclusionsSTS risk models overestimate contemporary SAVR risk at a high-volume center, supporting efforts to create a more agile quality assessment program. SAVR in low-risk patients provides durable survival benefit, supporting early surgery and providing a benchmark for transcatheter AVR. 相似文献
3.
《The Annals of thoracic surgery》2023,115(1):88-95
BackgroundRecent guidelines for the treatment of moderate or severe ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG) have changed. This study assessed the real-world impact of changing guidelines on the management of IMR during CABG over time. We hypothesized that the utilization of mitral valve repair for IMR would decrease over time, whereas mitral valve replacement for severe IMR would increase.MethodsPatients undergoing CABG in a statewide collaborative database (2011-2020) were stratified by severity of IMR. Trends in mitral valve repair or replacement were evaluated. To account for differences of the patients, propensity score–matched analyses were used to compare patients with and without mitral intervention.ResultsA total of 11,676 patients met inclusion criteria, including 1355 (11.6%) with moderate IMR and 390 (3.3%) with severe IMR. The proportion of patients undergoing mitral intervention for moderate IMR decreased over time (2011, 17.7%; 2020, 7.5%; Ptrend = .001), whereas mitral replacement for severe IMR remained stable (2011, 11.1%; 2020, 13.3%; Ptrend = .14). Major morbidity was higher for patients with moderate IMR who underwent mitral intervention (29.1% vs 19.9%; P = .005). In a propensity analysis of 249 well-matched pairs, there was no difference in major morbidity (29.3% with mitral intervention vs 23.7% without; P = .16) or operative mortality (1.2% vs 2.4%; P = .5).ConclusionsConsistent with recent guideline updates, patients with moderate IMR were less likely to undergo mitral repair. However, the rate of replacement for severe IMR did not change. Mitral intervention during CABG did not increase operative mortality or morbidity. 相似文献
4.
目的 研究胸段食管癌逆向调强放射治疗(IMRT)中累及野照射与扩大野照射对危及器官(OAR)受照剂量的影响。方法 40例胸段食管癌患者分别行累及野靶区勾画和扩大野靶区勾画并勾画危及器官,制定IMRT计划,评估2个计划的靶区适形指数(CI)和均匀性指数(HI)及危及器官的剂量学参数,剂量学参数比较采用配对t检验。结果 2种计划的PTV均能满足处方剂量要求,PTV在CI、HI上相近(P = 0.317、0.130)。两组间平均肺剂量、两肺V5、两肺V20、两肺V30、脊髓Dmean、心脏Dmean、心脏Dmax、心脏V30、心脏V40、心脏V60差异均存在统计学意义(P < 0.01)。结论 胸段食管癌患者行累及野照射与扩大野比较,可降低正常器官的受照剂量,从而降低放射性损伤风险。 相似文献
5.
目的 探讨情绪释放技术对改善乳腺癌术后化疗患者预期性悲伤的效果。方法 采用便利抽样法选取乳腺癌术后化疗患者60例为研究对象,采用随机数字表法将其分为对照组和干预组,各30例。对照组给予常规护理,干预组在对照组的基础上实施情绪释放干预疗法。比较干预前后2组心理痛苦程度和预期性悲伤得分水平。结果 干预后,干预组心理痛苦程度低于对照组(t=-17.930,P<0.001);预期性悲伤总分及各维度得分均低于对照组(P<0.001)。结论 对乳腺癌术后化疗患者应用情绪释放技术进行护理干预,可以减轻患者心理痛苦程度,降低患者预期性悲伤,值得临床推广应用。 相似文献
6.
Xiaoliang Bai Yong Lian Changqing Hu Shuai Yang Bo Pei Mingyan Yao Xiaojuan Zhu Lin Shang Zhihong Li 《Journal of applied toxicology : JAT》2022,42(7):1137-1145
Cyanidin-3-glucoside (C3G) is a well-known natural anthocyanin with antioxidant and anti-inflammatory properties. In this study, we explored the role and action mechanism of C3G in high glucose (HG)-induced damage of human nucleus pulposus cells (HNPCs). Cell viability was assessed by CCK-8 assay. TUNEL assay was performed for detecting apoptotic rate. Western blot was performed to determine the expression levels of cl-caspase-3, caspase-3, Bax, Bim, collagen II, aggrecan, MMP-3, MMP-13, and ADAMTS5. Reactive oxygen species (ROS) generation was analyzed using DCFH-DA staining. The Nrf2 was knocked down or overexpressed in HNPCs through transfection with si-Nrf2 or pcDNA3.0-Nrf2. C3G treatment (12.5, 25, and 50 μM) improved cell viability of HNPCs under HG condition. HG-induced cell apoptosis of HNPCs was attenuated by C3G with decreased apoptotic rate and relative levels of cl-caspase-3/caspase-3, Bax, and Bim. C3G treatment caused significant increase in expression levels of collagen II and aggrecan and decrease in the relative levels of MMP-3, MMP-13, and ADAMTS5. After treatment with C3G, ROS generation in HNPCs was markedly reduced. Treatment with N-acetylcysteine (NAC) reversed HG-induced cell apoptosis and extracellular matrix (ECM) degradation. C3G treatment induced the expression of Nrf2 and HO-1 in HG-induced HNPCs. Moreover, knockdown of Nrf2 reversed the inhibitory effect of C3G on ROS production. Summarily, C3G exerted a protective effect on ROS-mediated cellular damage in HNPCs under HG condition, which was attributed to the induction of the Nrf2/HO-1 signaling pathway. 相似文献
7.
《Journal of microbiology, immunology, and infection》2022,55(2):328-331
The ichroma? IGRA-TB (Boditech Med Inc., Chuncheon, Republic of Korea) is an automated fluorescent immunoassay-based point-of-care interferon-gamma release assay for detecting latent tuberculosis infection. We evaluated this assay with 408 health care workers, and demonstrated its acceptable performances comparing to QuantiFERON-TB Gold-Plus (QFT-Plus; Qiagen, Germantown, MD). 相似文献
8.
9.
10.
《European journal of surgical oncology》2020,46(6):982-990
IntroductionLung cancer is the leading cause of cancer-death worldwide. The U.S. Preventative Services Task Force (USPTSF) approved screening for current or former smokers aged 55–80 based on the results of the National Lung Screening trial (NLST). Following the NLST, new evidence has emerged from clinical trials and updates to previous trials prior to the anticipated update to the USPSTF guideline. We review the new evidence on lung cancer screening with low dose computed tomography (LDCT) and the surgical implications.MethodsA review of new literature was performed pertaining to lung cancer screening since implementation of UPSTF guidelines. Articles for inclusion were identified by both authors’, then search of the Pubmed and Cochrane database was performed from January 1st, 2013 through February 4th, 2020 using the MeSH search terms: “lung cancer”; “screening”; “low dose CT”. The results of these studies are summarized.ResultsWe identified multiple prospective randomized control trials and meta-analysis since the NLST supporting lung cancer-specific mortality with screening. We identified new nodule classification systems and the development of risk-models which may reduce false positive rates and identify high risk patients not currently eligible for screening. Finally, we discussed the surgical implications of screening.ConclusionNew data supports NLST findings and show ongoing benefit to LDCT for lung cancer screening. Standardized LDCT screening classification has been shown to reduce harm and lower false positive rates. Further study is needed regarding use of risk-modeling. Screening will require an increase in the thoracic workforce to accommodate the amount of surgically operable cancers. 相似文献